Sign in
EPRX Stock Price, Chart, Stats & News
Eupraxia Pharmaceuticals Inc.
Save
Eupraxia Pharmaceuticals Inc. (EPRX) does not currently pay a dividend.
220.63M
Market cap
–
Current P/E
–
Forward P/E
EPRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.05% |
ROA | -45.49% |
ROE | -74.34% |
D/E | 0.00x |
Interest coverage ratio | – |
EPRX valuation
P/E | – |
P/S | – |
P/B | 4.31x |
P/CF | -14.96x |
P/FCF | -9.45x |
P/OCF | -14.96x |
PEG | 0.26x |
EV multiple | -8.04x |
About
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis.
Similar securities
Based on sector and market capitalization
Report issue